Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly vs Daily Setmelanotide in Rare Genetic Obesity
NCT05194124Phase 3Completed
- Sponsor
- Rhythm Pharmaceuticals
- Start
- Dec 2021
- Primary completion
- Oct 2023
- Modality
- Peptides, Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial of setmelanotide in Bardet–Biedl syndrome (BBS), pro-opiomelanocortin deficiency, proprotein convertase subtilisin/kexin type 1 deficiency and 1 more (4 arms), sponsored by Rhythm Pharmaceuticals. Primary endpoints: Maximum Drug Concentration of Setmelanotide After QD Administration in the Run-in Period, Maximum Drug Concentration of Setmelanotide After QW Administration at Week 14 and 5 more. Started Dec 2021; status: completed.
02
Drugs
setmelanotide
03
Conditions
Bardet–Biedl syndrome (BBS)pro-opiomelanocortin deficiencyproprotein convertase subtilisin/kexin type 1 deficiencyleptin receptor deficiency
Beyond the preview
Go deeper on NCT05194124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05194124.